Yahoo Finance

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

NESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Ad Hoc News

MAPI stock: Mirae Asset sets IDR 1,890 target for Mitra Adiperkasa stock

Mirae Asset gave Mitra Adiperkasa an IDR 1,890 target on October 8, 2026, while the target stood 50.60 percent above the ...
Ad Hoc News

MAPI stock receives a Hold rating with IDR 1,700 target

MAPI stock was last at IDR 1,540 on October 8, 2026 at 2:40 p.m. WIB, down 0.65 percent on the Jakarta exchange. The immediate stock focus is an October 7 research note from MNC S ...
MarketWatch

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
irblog.prnewswire.com

Mapi Research Trust appointed as exclusive distributor and Mapi Language Services as exclusive translator of the "Disease Activity Score (DAS-28)"

LYON, France, July 7, 2017 /PRNewswire/ -- Mapi Research Trust, the leading curator and license distributor of Clinical Outcome Assessments (COAs) and Mapi Language Services, the most trusted provider ...
Nasdaq

Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis

Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies “Mapi Pharma and Mylan share a commitment to improve the lives of MS patients, and I am ...
manilatimes

Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables

NESS ZIONA, Israel, May 04, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd. ("Mapi” or the "Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today ...
Nasdaq

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 ...
idnfinancials

A month of accumulation, Samudra Investment now owns 31.13% of MAPI

Samudra Investment is MAPI's second-largest shareholder, behind its controlling shareholder, Pacific Universal Investment Pte. Ltd. (PUI), which continues to hold 51% of the company. Besides Samudra ...
manilatimes

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...